文献速递免疫规划

肯尼亚纳库鲁和蒙巴萨郡儿童引入季节性流感疫苗背景下的常规免疫覆盖率,2019-21:一项观察性研究

Routine immunisation coverage in the context of seasonal influenza vaccine introduction for children in Nakuru and Mombasa counties in Kenya, 2019-21: an observational study.
PubMed 文献 · Lancet Glob Health · 2025-01-01

该观察性研究在肯尼亚两个郡比较全年接种和宣传活动两种流感疫苗引入策略对常规免疫覆盖率的影响,纳入64家卫生机构。结果显示引入流感疫苗对肯尼亚扩大免疫规划中常规疫苗的接种率影响很小,但宣传活动模式下部分常规疫苗覆盖率有显著变化。

要点

  • 全年接种点MR第一剂覆盖率显著高于对照点(aRR 1.38,95%CI 1.27-1.49)。
  • 宣传活动模式点MR第一剂覆盖率显著低于对照点(aRR 0.98,95%CI 0.82-0.97)。
  • 引入流感疫苗对常规免疫规划疫苗接种率影响很小。

核心结论

  • 为合格儿童引入季节性流感疫苗对肯尼亚扩大免疫规划中常规疫苗的接种率影响很小。

研究设计与样本

  • 观察性研究,比较肯尼亚两个实施全年接种策略的县、两个实施宣传活动模式策略的县与两个未提供流感疫苗的对照县的数据。
  • 纳入64家卫生机构:28家(44%)全年接种点、12家(19%)宣传活动模式点、24家(38%)对照点。
  • 42家(66%)机构为二级机构,36家(56%)为政府所有。
  • 使用机构层面免疫接种记录表获取月度疫苗和补充剂接种剂次,并收集2018年11月1日至2019年10月31日(引入前1年)和2019年11月1日至2021年10月31日(示范期)的数据。
  • 采用负二项贝叶斯模型,调整时间段、机构所有权和卫生机构级别,比较参与与未参与流感疫苗示范项目的机构间常规免疫覆盖率。

主要发现

  • 引入前和示范期间,所有干预点Penta第1、2、3剂和MR第1剂覆盖率均超过65%;对照点Penta第1剂覆盖率为62.9%(95%CI 62.1-63.8),MR第1剂为64.0%(95%CI 63.1-64.9)。
  • 研究期间全年接种点MR第1剂覆盖率显著高于对照点(调整率比1.38,95%CI 1.27-1.49)。
  • 宣传活动模式点Penta第2剂(aRR 0.24 [95%CI 0.05-0.65])和MR第1剂(aRR 0.98 [95%CI 0.82-0.97])覆盖率显著低于对照点。
  • 干预点(全年接种和宣传活动模式)与对照点之间其他常规疫苗或补充剂覆盖率无显著差异。
  • 宣传活动模式点示范期间MR第1剂覆盖率显著低于实施前(率比0.75 [95%CI 0.70-0.80]),MR第2剂(RR 1.15,95%CI 1.06-1.24)和维生素A第2剂(RR 2.14 [95%CI 2.00-2.29])显著高于实施前;其他机构或其他剂次的变化无统计学显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on how the introduction of seasonal influenza vaccination for children might affect the coverage for other routine childhood immunisations are scarce. We assessed how introducing a new influenza vaccine for children aged 6-23 months in two counties in Kenya (Mombasa and Nakuru) affected the coverage rate for the diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b (pentavalent [Penta]) vaccine, measles-rubella (MR) vaccine, and vitamin A supplementation. METHODS: In this observational study, we compared data from two sub-counties in Kenya that implemented a year-round (ie, annual routine immunisation) influenza vaccine delivery strategy and two that implemented a campaign-mode delivery strategy with data from two control sub-counties where no influenza vaccine was provided. We used facility-level immunisation tally sheets to obtain counts of monthly vaccine and supplement doses given and monthly summary data to estimate the coverage rates. We collected data for 1 year before (from Nov 1, 2018 to Oct 31, 2019) and during the seasonal influenza vaccine demonstration period (from Nov 1, 2019 to Oct 31, 2021). We used negative binomial Bayesian models, adjusted for time period (before vs during the demonstration project), facility ownership, and level of health facility, to compare coverage rates for routine immunisations between health facilities that participated in the influenza vaccine demonstration project and those that did not. FINDINGS: Our study included 64 health facilities: 28 (44%) year-round, 12 (19%) campaign-mode, and 24 (38%) control sites. 42 (66%) of the facilities were level 2 (secondary) and 36 (56%) facilities were government owned. Before and during the influenza vaccine demonstration period, coverage rates for Penta doses one, two, and three and MR dose one were more than 65% in all the intervention sites; for comparison, in the control sites coverage was 62·9% (95% CI 62·1-63·8) for Penta dose one and 64·0% (63·1-64·9) for MR dose one. The coverage rate for MR dose one was significantly higher in the year-round sites versus the control sites across the timespan of the study (adjusted rate ratio 1·38, 95% CI 1·27-1·49), and the coverage rates for Penta dose two (aRR 0·24 [0·05-0·65]) and MR dose one (aRR 0·98 [0·82-0·97]) were significantly lower in the campaign-mode sites versus the control sites. There were no other significant differences in coverage rates for other routine vaccine or supplementation doses in the intervention (year-round and campaign-mode) versus the control sites. When comparing coverage before and during implementation of the influenza vaccination project, MR dose one coverage at the campaign-mode sites was significantly lower during the demonstration than before (rate ratio [RR] 0·75 [95% CI 0·70-0·80]), and MR dose two (RR 1·15, 1·06-1·24) and vitamin A dose two (RR 2·14 [2·00-2·29]) at the campaign-mode sites were significantly higher; none of the other changes before and during implementation at the other sites or for other doses were statistically significant. INTERPRETATION: The introduction of seasonal influenza vaccine for eligible children had a minimal effect on the uptake for routine vaccines in Kenya's Expanded Programme on Immunization. FUNDING: The Task Force for Global Health and The Centers for Disease Control and Prevention.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Igboh LS, Ayugi JO, Nyawanda BO, et al. Routine immunisation coverage in the context of seasonal influenza vaccine introduction for children in Nakuru and Mombasa counties in Kenya, 2019-21: an observational study. Lancet Glob Health. 2025. PMID: 40975081. doi:10.1016/S2214-109X(25)00265-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。